Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Anti-IgE monoclonal antibodies
16 evidence topics · 14 sources
Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline
“We recommend adding on omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for the treatment of patients with CU unresponsive to high doses of 2nd generation H1‐antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommended initial dose in CSU is 300 mg every 4 weeks as add on to antihistamine treatment. Dosing is independent of total serum IgE and bodyweight” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies support the use of omalizumab treatment at doses up to 600 mg and intervals of 2 weeks, in patients with insufficient response to standard dosed omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients need to be informed that omalizumab updosing is off‐label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug survival studies, or time to discontinuation, for omalizumab show that the main reason for discontinuation is due to well‐controlled disease and far less due to ineffectiveness or adverse effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved indication and dosage in chronic spontaneous urticaria: omalizumab
Anaphylaxis warning: omalizumab
Adverse reactions in pooled CSU trials, Day 1 to Week 12: omalizumab
| Adverse reaction | Omalizumab 150 mg (n=175) | Omalizumab 300 mg (n=412) | Placebo (n=242) |
|---|---|---|---|
| Nausea | “2 (1.1%)” | “11 (2.7%)” | “6 (2.5%)” |
| Nasopharyngitis | “16 (9.1%)” | “27 (6.6%)” | “17 (7.0%)” |
| Sinusitis | “2 (1.1%)” | “20 (4.9%)” | “5 (2.1%)” |
| Upper respiratory tract infection | “2 (1.1%)” | “14 (3.4%)” | “5 (2.1%)” |
| Arthralgia | “5 (2.9%)” | “12 (2.9%)” | “1 (0.4%)” |
| Headache | “21 (12.0%)” | “25 (6.1%)” | “7 (2.9%)” |
| Cough | “2 (1.1%)” | “9 (2.2%)” | “3 (1.2%)” |
Week 12 itch severity, hive count, and UAS7=0 in CSU Trial 1: omalizumab label
| Week 12 outcome | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo |
|---|---|---|---|---|
| N | “77” | “80” | “81” | “80” |
| Weekly itch severity score, mean change (SD) | “−6.46 (6.14)” | “−6.66 (6.28)” | “−9.40 (5.73)” | “−3.63 (5.22)” |
| Weekly itch severity score, difference in LS means vs placebo | “−2.96” | “−2.95” | “−5.80” | Not applicable |
| Weekly hive count score, mean change (SD) | “−7.36 (7.52)” | “−7.78 (7.08)” | “−11.35 (7.25)” | “−4.37 (6.60)” |
ASTERIA I: well-controlled UAS7 ⩽6 and complete response UAS7=0 with omalizumab 300 mg
“ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at licensed doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The omalizumab 300-mg group met all nine secondary end points, including a significant decrease in the duration of time to reach minimally important difference response (⩾5-point decrease) in weekly ISS ( P <0.0001) and higher percentages of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) ⩽6: 51.9% vs. 11.3% P <0.0001) and complete response (UAS7=0: 35.8% vs. 8.8% P <0.0001) versus placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 12 itch severity by omalizumab dose: phase 3 randomized trial
“In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Week 12 results with omalizumab 300 mg after antihistamines up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists
| Week 12 outcome | Omalizumab 300 mg (n = 252) | Placebo (n = 83) |
|---|---|---|
| Change from baseline in UAS7, mean (95% CI) | “−19.0 (−20.6 to −17.4)” | “−8.5 (−11.1 to −5.9)” |
| UAS7 ≤6, no. (%) | “132 (52.4)” | “10 (12.0)” |
| UAS7 = 0, no. (%) | “85 (33.7)” | “4 (4.8)” |
Pooled randomized trial effects of omalizumab 150 mg and 300 mg: systematic review
“This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world effectiveness and adverse events: meta-analysis of 67 observational studies
“Included studies were observational in design and included at least 1 outcome in common with other studies and at a concurrent time point of exposure to omalizumab. A total of 67 articles (35.2% of those screened) were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random-effects meta-analyses were performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab therapy was associated with an improvement in UAS7 scores (−25.6 points, 95% CI, −28.2 to −23.0; P < .001; 15 studies, 294 patients), an improvement in UAS scores (−4.7 points, 95% CI, −5.0 to −4.4, P < .001; 10 studies, 1158 patients), an average complete response rate of 72.2% (95% CI, 66.1%-78.3%; P < .001; 45 studies, 1158 patients) with an additional average partial response rate of 17.8% (95% CI, 11.7%-23.9%; P < .001; 37 studies, 908 patients), and an average adverse event rate of 4.0% (95% CI, 1.0%-7.0%; P < .001; any level of severity, 47 studies, 1314 patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug survival and reasons for discontinuation: meta-analysis of 8 observational studies
“Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update
Omalizumab 300 mg compared with dupilumab and remibrutinib: network meta-analysis of 15 studies
“This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequentist random-effects network meta-analysis were conducted in R.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lower omalizumab doses lacked durability at 24 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ligelizumab not superior to omalizumab: PEARL-1 and PEARL-2 phase 3 trials
“PEARL-1 and PEARL-2 were identically designed randomised, double-blind, active-controlled and placebo-controlled parallel-group studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Oct 17, 2018, and Oct 26, 2021, 2057 adult patients were randomly allocated across both studies (72 mg ligelizumab n=614; 120 mg ligelizumab n=616; 300 mg omalizumab n=618, and placebo n=209).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both doses of ligelizumab were superior to placebo (p<0·0001), but not to omalizumab, in both studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 3 PEARL studies, ligelizumab demonstrated superior efficacy versus placebo but not versus omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab biosimilar omalizumab-igec: FDA-approved indication in chronic spontaneous urticaria
Biosimilar CT-P39 compared with reference omalizumab: randomized active-controlled phase 3 equivalence trial
“This double‐blind, randomized, active‐controlled Phase 3 study ( NCT04426890 ) included two 12‐week treatment periods (TPs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In TP1, 619 patients were randomized (CT‐P39 300 mg, n = 204; ref‐OMA 300 mg, n = 205; CT‐P39 150 mg, n = 107; ref‐OMA 150 mg, n = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote